Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: An updated systematic review and meta-analysis with trial sequential analysis

Ayako Yokoi¹, Takahiro Mihara¹,²*, Koui Ka¹, Takahisa Goto²

¹ Department of Anesthesiology, Kanagawa Children’s Medical Center, Minami-ku, Yokohama, Japan, ² Department of Anesthesiology and Critical Care Medicine, Kanazawa-ku, Yokohama City University Graduate School of Medicine, Yokohama, Japan

* miharaxxtotoro@yahoo.co.jp

Abstract

Background
Postoperative nausea and vomiting is a distressing complication of surgery, and 5-HT₃ receptor antagonists are often prescribed to prevent it. Ondansetron is the agent typically administered to prevent postoperative nausea and vomiting. Although ramosetron has a longer duration of action than ondansetron, it remains unclear whether ramosetron is the more effective medication. We performed an updated meta-analysis on the comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting.

Methods
We searched six databases for all trials that randomly assigned patients to ramosetron or ondansetron groups. The primary outcome was postoperative nausea or vomiting in the early, late, and next-day periods. The secondary outcomes were side effects of the medications. We used the random-effects model to combine the results. Trial sequential analyses were performed to correct for repetitive testing in the updated meta-analysis.

Results
Twenty-seven randomized controlled trials with 3,811 patients were included in the meta-analysis. The combined results of ramosetron vs. ondansetron efficacy in preventing postoperative nausea and vomiting were as follows: Risk ratio [95% confidence interval] = 0.82 [0.69–0.98] for early postoperative nausea, 0.76 [0.65–0.89] for late postoperative nausea, 0.69 [0.57–0.84] for next-day postoperative nausea, 0.78 [0.63–0.98] for early postoperative vomiting, 0.57 [0.45–0.72] for late postoperative vomiting, and 0.61 [0.43–0.86] for next-day postoperative vomiting. Dizziness was significantly lower in ramosetron groups than in ondansetron groups (risk ratio [95% confidence interval] = 0.81 [0.66–0.98]). Trial
sequential analysis revealed that the results for late postoperative nausea, late postoperative vomiting, and next-day postoperative nausea were conclusive.

Conclusions
Ramosetron is more effective in preventing late postoperative nausea, late postoperative vomiting, and next-day postoperative nausea than ondansetron. The incidence of dizziness may be lower in patients receiving ramosetron than in patients receiving ondansetron.

Trial registration
University hospital Medical Information Network Clinical Trials Registry: UMIN000022980

Introduction
Postoperative nausea (PON) and postoperative vomiting (POV) are common and distressing complications after surgery. The guideline [1] for the management of postoperative nausea and vomiting (PONV) recommends the use of prophylactic agents, including 5-HT₃ receptor antagonists, for patients with a high risk of PONV.

Ramosetron is a 5-HT₃ receptor antagonist which displays more prolonged activity than other 5-HT₃ antagonists, such as ondansetron [2]. Previously, we reported results of the meta-analysis of the effects of ramosetron in preventing PON and POV [3]; the combined results with 637 patients (six studies) showed that ramosetron had a statistically significant effect on early POV (risk ratio [95% confidence interval] = 0.50 [0.28–0.90]) and late POV (0.53 [0.34–0.81]) but not early PON (0.79 [0.51–1.23]) and late PON (0.78 [0.60–1.46]) compared with 4 mg of ondansetron. Although ramosetron was reported to be more effective than ondansetron in preventing POV [3,4], an updated meta-analysis is required because several randomized controlled trials (RCTs) have been published since then. The Cochrane Handbook recommends that systematic reviews be updated within two years, because "systematic reviews that are not maintained may become out of date or misleading" [5]. In addition, these previous studies [3,4] looked only at RCTs which prescribed 4 mg of ondansetron. Ryu et al. reported that 8 mg of ondansetron were equally as effective as ramosetron in preventing PONV [6]. Thus, we elected to include multiple dose regimens in the current meta-analysis.

When updating a meta-analysis, the use of heterogeneity-adjusted trial sequential analysis (TSA) [7–11] is recommended because TSA-adjusted confidence intervals (CIs) can prevent inflation of the type I error rate from repetitive testing. Consequently, TSA reduces the risk of false positives in meta-analyses [7,9].

The aim of this study was to conduct an updated meta-analysis, using TSA to compare the efficacy of ramosetron and ondansetron (4-mg and 8-mg doses) in preventing PONV.

Materials and methods
We conducted a meta-analysis following the PRISMA statement [12,13] and Cochrane Handbook [5] guidelines. Our study protocol and analysis methods were pre-specified and registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (registration number: UMIN000022980).
Search strategy

**Databases searched.** We searched the same databases as those included in our previous meta-analysis [3]: MEDLINE, the Cochrane Central Register of Controlled Trials, Embase, and Web of Science. The reference lists of the retrieved full articles were also searched. We then conducted a search of clinicaltrials.gov and the UMIN Clinical Trials Registry. We searched these databases on August 11, 2017.

**Search terms and screening strategy.** The search strategy was constructed by combining the following terms, as well as their synonyms: Ramosetron, postoperative, nausea, vomiting, and RCT. The details of the search strategy can be found in our previous meta-analysis [3]. To reduce screening errors, we adopted a double-check system. Two authors independently checked the titles and abstracts of RCTs identified by the initial search. Studies which were considered eligible or studies where eligibility could not be determined by checking the title or abstract were evaluated in full-text versions. The studies that met the inclusion criteria were assessed separately by two authors. Discrepancies were resolved through discussion.

Study eligibility

We searched for all trials that randomly assigned patients to ramosetron and ondansetron groups. The exclusion criteria were the same as in our previous meta-analysis: “Trials reported by Fujii et al.; trials which did not include details of PON and/or POV; trials which did not include details of the incidence at the early, late, and/or next-day periods” [3]. We did not apply an English-language restriction.

The primary outcomes were PON and/or POV in the early, late, and next-day periods. The secondary outcomes were side effects of the medications.

The definition of the early and late period was the same as in our previous systematic review: “When the first postoperative 24 h are divided into two time periods (e.g., 0–6 hours and 6–24 h), the first time period is defined as the early period and the second time period as the late period. When the first postoperative 24 h are divided into three parts, the time period just before 6 h is defined as the early period, and the time period just after 6 h as the late period (e.g., when 24 h are divided into 0–6, 6–12, and 12–24 h, we define 0–6 h as the early period, and 6–12 h as the late period)” [3]. The next-day period was defined as 24–48 hours after surgery.

Data abstraction

A data extraction sheet was created and included data about participants (e.g., age, American Society of Anesthesiologists [ASA] physical status), type of surgery, anesthesia use, drug treatment (dose and route of administration), primary and secondary outcomes of the study, side effects of the medications, and funding information. The data extraction strategy was the same as in our previous study: “Values originally provided as percentages were converted back into actual patient numbers for analysis. If the data were reported only in graphs which indicated percentages or numbers of patients, we measured the lengths of the graphs to obtain the percentages or numbers of patients. If ramosetron was administered by different routes or at different dosages in the same study, data with 0.3 mg of intravenous ramosetron were used because these are the most common routes and dosages” [3]. Studies in which a baseline antiemetic was used were included, and a study evaluating baseline drug plus ramosetron treatment against baseline drug plus ondansetron treatment was counted as a ramosetron vs. ondansetron study.

If ondansetron was administered at different doses, we combined the dose groups into a single group for our primary analysis. We then conducted a subgroup analysis with an
interaction analysis according to the ondansetron dose. For this purpose, the data were re-
extracted when ondansetron was administered at different doses. The data in each ondanse-
tron dose group were extracted separately, and the data from the ramosetron group were
divided according to the number of ondansetron groups to avoid double-counting. Two
authors extracted the data independently from the studies included and then crosschecked for
discrepancies.

Assessment of bias risk

We assessed the risk of bias as described by the Cochrane Handbook for Systematic Reviews of
Interventions [5]. The following domains were assessed for bias risk: “Sequence generation”,
“allocation sequence concealment”, “blinding”, “incomplete outcome data”, “selective out-
come reporting”, and “other bias.” We assessed “summary risk of bias”. We assessed the sum-
mary risk of bias as “low” for RCTs with a low risk of bias in all domains; “high” for RCTs with
a high risk of bias in at least one domain; “unclear” for RCTs that were neither “low” nor
“high” in summary risk of bias.

Assessment of quality of evidence

We graded the quality of evidence of the main outcomes using the Grading of Recommend-
ations Assessment, Development, and Evaluation (GRADE) approach [14,15] with GRADEpro
software (version 3.6 for Windows; available from http://ims.cochrane.org/revman/gradepro). Assessments of the quality of evidence were based on the presence or absence of the following
variables: Limitations in study design, inconsistencies, indirectness, imprecision in the results,
and publication bias. Evidence quality for the main outcomes was graded as very low, low,
moderate, or high.

Statistical analysis

A risk ratio (RR) with a 95% CI was used as a summary measure for dichotomous data. The
random-effects model (DerSimonian and Laird method) [16] was used for combining the
results of the trials. Heterogeneity was quantified with the $I^2$ statistic. We considered that sig-
nificant heterogeneity existed when the $I^2$ statistic exceeded 50%. Small-study effects, including
publication bias, were evaluated by creating a funnel plot. In addition, we applied Egger’s
asymmetry test [17] to each funnel plot. Subgroup analyses were performed according to the
bias risk (low vs. high or unclear) and ondansetron dose (4 mg vs. 8 mg).

TSAs [7–11] were performed to prevent false-positive or false-negative results from repeti-
tive testing. TSA monitoring boundaries for meta-analysis and required information size (RIS)
were quantified, and adjusted CIs were calculated. The RIS indicates a target sample size con-
sidering the heterogeneity of the data. To perform the TSA, we set the risk of type I error at 5%
and of type II error at 10% (i.e., 90% power). The incidence of PON or POV in the control
group was based on that of the included trials, and a clinically meaningful risk reduction of
25%, which was determined from a clinical perspective, was used. If the cumulative Z-curve
crossed the TSA-monitoring boundary, we considered that the false-positive result rate was
less than 5%. If the cumulative Z-curve crossed the futility boundary, we considered the risk
ratio of ramosetron vs. ondansetron preference for the primary outcomes to be no less than
0.75, because we set a clinically meaningful anticipated relative risk reduction at 25%. If the
95% CI or the TSA-adjusted CI included a value of 1, we considered the difference to be not
statistically significant. Statistical significance was set at $p < 0.1$ for the funnel plot asymmetry
test.
Statistical analyses were performed using the R statistical software package, version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria). TSA was performed using TSA viewer version 0.9.5.5 β (www.ctu.dk/tsa).

Results

Search results

Our search of MEDLINE, the Cochrane Central Register of Controlled Trials, Embase, Web of Science, clinicaltrials.gov, and the UMIN Clinical Trials Registry databases produced 602 citations. The full texts of 61 articles were examined in detail. We included 27 RCTs [6,18–43] with 3,811 patients (Fig 1). Of the 27 studies, 23 were available in English and four [32,34,36,37] in Korean. The PRISMA checklist is provided in the supporting information (S1 Table).
Study characteristics

The details of the 27 RCTs are presented in Table 1. The participants were adults in 26 RCTs and children in one RCT [26]. Surgical procedures varied among the RCTs and included minor surgery, laparoscopic surgery, orthopedic surgery, major abdominal surgery, pulmonary lobectomy, craniotomy, and cardiac surgery. The ondansetron dose was 4 mg in 13 RCTs [18,21,24,25,27,28,30–32,37,39,41,42], 8 mg in five RCTs [19,22,33,36,40], both 4 mg and 8 mg in three RCTs [6,20,23], and other doses in six RCTs [26,29,34,35,38,43]. All RCTs used 0.3 mg of ramosetron except for four studies [26,29,34,35].

Early PON

Twenty-three RCTs with 2,211 patients (1,050 patients in ramosetron groups and 1,161 patients in ondansetron groups) were analyzed for drug efficacy in preventing early-period PON (Fig 2). The combined results showed that ramosetron was significantly more effective in preventing early PON than ondansetron (RR [95% CI] = 0.82 [0.69–0.98], I² = 31%) (Fig 2A).

When the analysis was restricted to RCTs with a low bias risk, ramosetron was more effective in preventing early PON than ondansetron (RR [95% CI] = 0.72 [0.53–0.98]). The subgroup difference according to the bias risk was not statistically significant (p = 0.25). The subgroup analysis revealed that there was a significant difference between 4-mg and 8-mg ondansetron treatment (p = 0.002, Table 2). Ramosetron was more effective in preventing early PON than 4-mg ondansetron, but similar to 8-mg ondansetron (Table 2).

The Z-curve did not cross the TSA monitoring boundary or the futility boundary (Fig 2B). The TSA-adjusted CI was 0.67–1.01, indicating the imprecision of the study. The accrued information size (n = 2,211) was 80% of the RIS (n = 2,771).

The GRADE was determined to be “low” because TSA indicated imprecise results; the funnel plot analysis, described below, indicated a suspicion of small-study effects.

Late PON

Twenty-three RCTs with 2,211 patients (1,050 patients in ramosetron groups and 1,161 patients in ondansetron groups) were analyzed for drug efficacy in preventing late-period PON (Fig 3). The combined results showed that ramosetron was significantly more effective at preventing late PON than ondansetron (RR [95% CI] = 0.76 [0.65–0.89], I² = 20%) (Fig 3A).

When the analysis was restricted to RCTs with a low risk of bias, it yielded a similar result (RR [95% CI] = 0.69 [0.50–0.97]). The subgroup difference according to the bias risk was not statistically significant (p = 0.43). The subgroup analysis revealed that the difference in efficacy between 4-mg and 8-mg ondansetron was not statistically significant (p = 0.20, Table 2).

The Z-curve crossed the TSA monitoring boundary (Fig 3B). The TSA-adjusted CI was 0.64–0.90. The accrued information size (n = 2,211) reached the RIS (n = 2,179).

The GRADE was determined to be “moderate” because the funnel plot analysis, described below, indicated a suspicion of small-study effects.

Next-day PON

Eighteen RCTs with 1,707 patients (798 patients in ramosetron groups and 909 patients in ondansetron groups) were analyzed for ramosetron and ondansetron efficacy in preventing next-day PON (Fig 4). The combined results showed that ramosetron had significantly greater efficacy in preventing next-day PON than ondansetron (RR [95% CI] = 0.69 [0.57–0.84], I² = 0%) (Fig 4A).
Table 1. Characteristics of trials included in the meta-analysis.

|            | ASA-PS | Age | Total number of patients | Surgery                                                                 | Type of anesthesia | Route of administration | Timing of administration | Definition of early period (h) | Definition of late period (h) | Ramosetron dose | Ondansetron dose | Funding                      |
|------------|--------|-----|--------------------------|-------------------------------------------------------------------------|--------------------|--------------------------|----------------------------|--------------------------------|----------------------------|----------------|-----------------|----------------------------|
| Mujoo et al., 2017 [38] | 1–2    | 20–60 | 100                      | elective urological procedures                                         | N2O, isoflurane    | iv                       | just before extubation         | 0–6                             | 6–12                         | 0.3 mg         | 6 mg            | None                        |
| Pinsomsak et al., 2017 [40] | 1–3    | 50–80 | 90                       | total knee arthroplasty                                                 | spinal anesthesia  | iv                       | 10 min before spinal anesthesia | 0–6                             | 6–12                         | 0.3 mg         | 8 mg            | None                        |
| Suman et al., 2017 [39] | 1–2    | 18–40 | 100                      | caesarean section                                                       | spinal anesthesia  | iv                       | after clamping of umbilical cord | 0–6                             | 6–24                         | 0.3 mg         | 4 mg            | Not reported               |
| Joo et al., 2016 [41] | 1–2    | 18–60 | 58                       | strabismus                                                              | sevoflurane, remifentanil | iv                       | at the end of surgery           | 0–2                             | 2–24                         | 0.3 mg         | 4 mg            | Not reported               |
| Jamwal et al., 2016 [42] | 1–2    | 25–55 | 100                      | Laparoscopic cholecystectomy                                            | N2O, atracurium    | iv                       | 3 min before induction of anaesthesia | 2–6                             | 6–12                         | 0.3 mg         | 4 mg            | None                        |
| Lee et al., 2015 [20] | 1–2    | 20–75 | 62                       | microvascular decompression with retromastoid craniotomy                | sevoflurane, remifentanil | iv                       | at the onset of dural closure   | 1–6                             | 6–24                         | 0.3 mg         | 8 mg            | Company (Astellas Pharma Korea) |
| Shetty et al., 2015 [21] | 1–2    | 15–60 | 150                      | middle ear surgery                                                      | general anesthesia | iv                       | after surgery                  | 2–6                             | 6–24                         | 0.3 mg         | 4 mg            | None                        |
| Agarkar and Chatterjee, 2015 [22] | 1–2   | 48.2 (SD 13.6) | 206                      | breast, parotid, thyroid, or gynecological surgery                     | isoflurane, N2O    | iv                       | 30 min before the end of surgery | 0–6                             | 6–24                         | 0.3 mg         | 8 mg            | Company (Cadila Healthcare Ltd.) |
| Shin et al., 2015 [20] | 1–2    | 20–75 | 117                      | orthopedic surgery                                                      | spinal anesthesia  | iv                       | 5 min before spinal anesthesia | 0–2                             | 2–24                         | 0.3 mg         | 4 mg and 8 mg    | Company (Astellas Pharma Korea) |
| Gupta et al., 2014 [43] | 1–2    | 20–65 | 60                       | surgery under general anesthesia                                        | N2O, halothane     | iv                       | 5 min prior to induction of anaesthesia | 0–3                             | 3–24                         | 0.3 mg         | 0.1 mg/kg       | None                        |
| Kaja et al., 2014 [24] | 1–2    | 18–60 | 60                       | major abdominal surgeries                                               | inhalational agent, fentanyl | iv                       | before extubation               | 0–6                             | 6–24                         | 0.3 mg         | 4 mg            | None                        |
| Ryu et al., 2014 [23] | 1–2    | 19–65 | 127                      | elective craniotomy                                                     | TIVA with propofol and remifentanil | iv                       | at the end of surgery           | 0–2                             | 2–24                         | 0.3 mg         | 4 mg and 8 mg    | None                        |
| Kim et al., 2012 [25] | 1–2    | 20–65 | 109                      | elective laparoscopic surgery                                           | sevoflurane, remifentanil | iv                       | before anesthesia              | 0–6                             | 6–24                         | 0.3 mg         | 4 mg            | Not reported               |
| Park et al., 2013 [26] | 1–2    | 2–15  | 218                      | elective orthopedic surgeries                                           | sevoflurane, N2O   | iv                       | at the end of surgery           | 0–6                             | 6–24                         | 6 mcg/kg       | 100 mcg/kg       | None                        |
| Choi et al., 2012 [27] | 1–2    | 20–65 | 120                      | lumbar spine surgery                                                    | sevoflurane         | iv                       | at the end of surgery           | 0–6                             | 6–24                         | 0.3 mg         | 4 mg            | Not reported               |
| Lee et al., 2011 [28] | 1–2    | 18–60 | 120                      | abdominal hysterectomy                                                  | sevoflurane, N2O   | iv                       | at the end of surgery           | 0–2                             | 2–24                         | 0.3 mg         | 4 mg            | Not reported               |

(Continued)
| Study                  | ASA-PS    | Age          | Total number of patients | Surgery                  | Type of anesthesia | Route of administration | Timing of administration | Definition of early period (h) | Definition of late period (h) | Ramosetron dose | Ondansetron dose | Funding                      |
|-----------------------|-----------|--------------|--------------------------|--------------------------|--------------------|-------------------------|----------------------------|-----------------------------|-------------------------|-----------------|------------------|-----------------------------|
| Ansari et al., 2010   | 1–2       | 30–50        | 130                      | laparoscopic cholecystectomy | sevoflurane, N₂O | iv                      | at the end of surgery    | NA                          | NA                      | 0.3 mg          | 4 mg             | Not reported             |
| Choi et al., 2010     | Not reported | Adult (approximately 80 years) | 279 | cardiac surgery | TIVA | iv | at the end of surgery | 0–6 | 6–24 | 0.3 mg + 0.6 mg in PCA | 4 mg + 12 mg in PCA | departmental |
| Hahm et al., 2010     | 1–3       | Approximately 60 years | 84 | total knee replacement | CSEA + propofol (0.5–2.0 mcg/mL) | iv | at the end of surgery | 0–6 | 6–24 | 0.3 mg | 4 mg | None |
| Ryu et al., 2010      | 1–2       | 25–65        | 120                      | laparoscopic cholecystectomy | desflurane      | iv                      | at the end of surgery    | 0–2 | 2–24 | 0.3 mg | 4 mg and 8 mg | Not reported |
| Kim et al., 2009      | Not reported | 21–71        | 162                      | gynecological surgery | sevoflurane, N₂O | iv | at the end of surgery | 0–6 | 6–24 | 0.3 mg | 8 mg | Not reported |
| Yoon et al., 2009     | 1–2       | 30–65        | 70                       | middle ear surgery | sevoflurane, remifentanil | iv | at the end of surgery | 0–6 | 6–24 | 0.3 mg | 4 mg | Not reported |
| Choi et al., 2008     | Not reported | 18–65        | 94                       | lumbar spine surgery | general anesthesia | iv | at the end of surgery | 0–6 | 6–24 | 0.3 mg + saline in PCA + 0.3 mg (24 h) | 4 mg + 12 mg in PCA + saline (24 h) | None |
| Lee et al., 2008      | 1–2       | 18–65        | 150                      | elective surgery | sevoflurane, N₂O | oral | before induction | 0–6 | 6–24 | 0.1 mg ODT | 4 mg + 8 mg in PCA | Not reported |
| Suh et al., 2007      | 1–2       | 30–65        | 58                       | gynecologic surgery | sevoflurane, N₂O | iv | at the end of surgery | 0–3 | 3–24 | 0.3 mg | 8 mg | Not reported |
| Huh et al., 2006      | 2–3       | 57.1 ± 11.6  | 65                       | lobectomy | general with epidural anesthesia | iv | at the end of surgery | 0–6 | 6–24 | 0.3 mg | 4 mg | Not reported |

ASA, American Society of Anesthesiologists; PS, physical status; CSEA, combined spinal-epidural analgesia; NA, not available; PCA, patient-controlled analgesia; TIVA, total intravenous anesthesia; SD, standard deviation.

https://doi.org/10.1371/journal.pone.0186006.t001
**Fig 2.** Forrest plot and trial sequential analysis of postoperative nausea (PON) in the early period. (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the early-period PON was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g002
When the analysis was restricted to RCTs with a low risk of bias, it yielded a similar result (RR [95% CI] = 0.59 [0.36–0.95]). The subgroup difference according to the bias risk was not statistically significant ($p$ = 0.43). The subgroup analysis revealed that the difference between 4-mg and 8-mg ondansetron was not statistically significant ($p$ = 0.72, Table 2).

The Z-curve crossed the TSA monitoring boundary (Fig 4B). The TSA-adjusted CI was 0.54–0.89. The accrued information size ($n = 1,707$) was 75% of the RIS ($n = 2,261$).

The GRADE was determined to be “high” because there was no inconsistency, imprecision, indirectness, suspicion of biased result from high or unclear risk of bias, or suspicion of publication bias.

### Early POV

Twenty-two RCTs with 2,298 patients (1,089 patients in ramosetron groups and 1,209 patients in ondansetron groups) were analyzed for ramosetron and ondansetron efficacy in preventing early-period POV (Fig 5). The combined results showed that ramosetron was significantly more effective in preventing early POV than ondansetron (RR [95% CI] = 0.78 [0.63–0.98], $I^2 = 0\%$) (Fig 5A).

When the analysis was restricted to RCTs with a low bias risk, it yielded a similar result, but the 95% CI widened (RR [95% CI] = 0.76 [0.54–1.09]). The subgroup difference according to the bias risk was not statistically significant ($p = 0.86$). The subgroup analysis revealed that the difference in efficacy between 4-mg and 8-mg ondansetron was not statistically significant ($p = 0.26$, Table 2).

The Z-curve did not cross the TSA monitoring boundary or the futility boundary (Fig 5B). The TSA-adjusted CI was 0.55–1.11. The accrued information size ($n = 2,298$) was 49% of the RIS ($n = 4,647$).

The GRADE was determined to be “low” because the TSA indicated that the result was imprecise.

### Late POV

Twenty-two RCTs with 2,298 patients (1,089 patients in ramosetron groups and 1,209 patients in ondansetron groups) were analyzed for ramosetron and ondansetron efficacy in preventing late-period POV (Fig 6). The combined results showed that ramosetron was significantly more effective in preventing late-period POV than ondansetron (RR [95% CI] = 0.57 [0.45–0.72], $I^2 = 0\%$) (Fig 6A).
Fig 3. Forrest plot and trial sequential analysis of postoperative nausea (PON) in the late period. (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the late-period PON was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g003
Fig 4. Forrest plot and trial sequential analysis of postoperative nausea (PON) in the next-day period. (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the next-day period PON was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g004
**A**

| Study          | Ramosetron Events | Total  | Ondansetron Events | Total  | Risk Ratio | RR   | 95% CI  |
|----------------|-------------------|--------|--------------------|--------|------------|------|---------|
| Jamwal 2016    | 4                 | 50     | 2                  | 50     | 2.00       | 2.00 | [0.38; 10.43] |
| Mujoo 2017     | 0                 | 50     | 2                  | 50     | 0.20       | 0.20 | [0.01; 4.06]  |
| Gupta 2014     | 2                 | 30     | 4                  | 30     | 0.50       | 0.50 | [0.10; 2.53]  |
| Pinsornsk 2017 | 21                | 45     | 24                 | 45     | 0.88       | 0.88 | [0.58; 1.33]  |
| Suman 2017     | 0                 | 50     | 3                  | 50     | 0.14       | 0.14 | [0.01; 2.70]  |
| Ha 2015        | 7                 | 31     | 4                  | 31     | 1.75       | 1.75 | [0.57; 5.38]  |
| Agarkar 2015   | 24                | 103    | 29                 | 103    | 0.83       | 0.83 | [0.52; 1.32]  |
| Shin 2015      | 0                 | 39     | 0                  | 78     | 0.33       | 0.33 | [0.07; 1.52]  |
| Kaja 2014      | 2                 | 30     | 6                  | 30     | 1.01       | 1.01 | [0.09; 10.84] |
| Ryu 2014       | 1                 | 42     | 2                  | 85     | 0.50       | 0.50 | [0.13; 1.95]  |
| Park 2013      | 3                 | 109    | 6                  | 109    | 1.00       | 1.00 | [0.21; 4.76]  |
| Choi 2012      | 3                 | 60     | 3                  | 60     | 0.50       | 0.50 | [0.13; 1.95]  |
| Lee 2011       | 1                 | 60     | 2                  | 60     | 1.00       | 1.00 | [0.21; 4.76]  |
| Choi 2010      | 5                 | 68     | 4                  | 71     | 1.31       | 1.31 | [0.37; 4.66]  |
| Hahn 2010      | 5                 | 42     | 8                  | 42     | 0.62       | 0.62 | [0.22; 1.75]  |
| Ryu 2010       | 1                 | 40     | 10                 | 80     | 0.20       | 0.20 | [0.03; 1.51]  |
| Kim 2009       | 4                 | 54     | 8                  | 54     | 0.50       | 0.50 | [0.16; 1.56]  |
| Yoon 2009      | 2                 | 35     | 4                  | 35     | 0.50       | 0.50 | [0.10; 2.56]  |
| Choi 2008      | 2                 | 47     | 9                  | 47     | 0.22       | 0.22 | [0.05; 0.97]  |
| Lee 2008       | 4                 | 50     | 2                  | 50     | 2.00       | 2.00 | [0.38; 10.43] |
| Suh 2007       | 9                 | 29     | 10                 | 29     | 0.90       | 0.90 | [0.43; 1.88]  |
| Huh 2006       | 0                 | 25     | 1                  | 20     | 0.27       | 0.27 | [0.01; 6.24]  |

Random effects model  
Heterogeneity: *I*-squared = 0%

**B**

![Forrest plot](https://doi.org/10.1371/journal.pone.0186006.g005)

**Fig 5. Forrest plot and trial sequential analysis of postoperative vomiting (POV) in the early period.** (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the early-period POV was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g005
When the analysis was restricted to RCTs with low bias risk, it yielded a similar result (RR [95% CI] = 0.59 [0.40–0.87]). The subgroup difference according to the bias risk was not statistically significant (p = 0.80). The subgroup analysis revealed that the difference in efficacy between 4-mg and 8-mg ondansetron was not statistically significant (p = 0.61, Table 2).

The Z-curve crossed the TSA monitoring boundary (Fig 6B). The TSA-adjusted CI was 0.42–0.78. The accrued information size (n = 2,298) was 66% of the RIS (n = 3,499).

The GRADE was determined to be “high” because there was no inconsistency, imprecision, indirectness, suspicion of biased result from high or unclear risk of bias, or suspicion of publication bias.

Next-day POV

Seventeen RCTs with 1,794 patients (837 patients in ramosetron groups and 957 patients in ondansetron groups) were analyzed for ramosetron and ondansetron efficacy in preventing next-day POV (Fig 7). The combined results showed that ramosetron was significantly more effective in preventing next-day POV than ondansetron (RR [95% CI] = 0.61 [0.43–0.86], I² = 0%) (Fig 7A).

When the sensitivity analysis was restricted to RCTs with low bias risk, it yielded a similar result, but the 95% CI widened (RR [95% CI] = 0.44 [0.19–1.05]). The subgroup difference according to the bias risk was not statistically significant (p = 0.43). The subgroup analysis revealed that the difference in efficacy between 4-mg and 8-mg ondansetron was not statistically significant (p = 0.76, Table 2).

The Z-curve did not cross the TSA monitoring boundary or the futility boundary (Fig 7B). The TSA-adjusted CI was 0.31–1.19. The accrued information size (n = 1,794) was 30% of the RIS (n = 5,980).

The GRADE was determined to be “low” because the TSA indicated that the result was imprecise.

Side effects

Eighteen RCTs with 2,871 patients (1,423 patients in ramosetron groups and 1,448 patients in ondansetron groups) were analyzed for headache as a side effect (Fig 8). The combined results showed that the incidence of headache did not differ significantly between ramosetron and ondansetron treatment groups (RR [95% CI] = 1.00 [0.78–1.28], I² = 0%) (Fig 8A). The subgroup analysis revealed that the differences according to bias risk and ondansetron dose (4 mg vs. 8 mg) were not statistically significant (p = 0.79 and 0.73, respectively). The Z-curve did not cross the TSA monitoring boundary or the futility boundary (TSA-adjusted CI = 0.67–1.49, Fig 8B). The GRADE was determined to be “low” because the TSA indicated that the result was imprecise.

Twenty-one RCTs with 3,105 patients (1,521 patients in ramosetron groups and 1,584 patients in ondansetron groups) were analyzed for dizziness as a side effect (Fig 9). The combined results showed that the incidence of dizziness was lower in patients receiving ramosetron than in patients receiving ondansetron (RR [95% CI] = 0.81 [0.66–0.98], I² = 0%) (Fig 9A). The subgroup analysis revealed that the differences according to bias risk and ondansetron dose (4 mg vs. 8 mg) were not statistically significant (p = 0.71 and 0.60, respectively). The Z-curve did not cross the TSA monitoring boundary or the futility boundary (TSA-adjusted CI = 0.62–1.04, Fig 9B). The GRADE was determined to be “low” because the TSA indicated that the result was imprecise.

Fifteen RCTs with 2,484 patients (1,209 patients in ramosetron groups and 1,275 patients in ondansetron groups) were analyzed for drowsiness as a side effect (Fig 10). The combined results showed that the incidence of drowsiness was lower in patients receiving ramosetron than in patients receiving ondansetron (RR [95% CI] = 0.57 [0.43–0.76], I² = 0%) (Fig 10A). The subgroup analysis revealed that the differences according to bias risk and ondansetron dose (4 mg vs. 8 mg) were not statistically significant (p = 0.81 and 0.71, respectively). The Z-curve did not cross the TSA monitoring boundary or the futility boundary (TSA-adjusted CI = 0.67–1.49, Fig 10B). The GRADE was determined to be “low” because the TSA indicated that the result was imprecise.
Fig 6. Forrest plot and trial sequential analysis of postoperative vomiting (POV) in the late period. (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the late-period POV was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g006
A

| Study            | Ramosetron Events | Total | Ondansetron Events | Total | Risk Ratio | RR   | 95% - CI          |
|------------------|-------------------|-------|--------------------|-------|------------|------|------------------|
| Jamwal 2016      | 13                | 50    | 19                 | 50    | 0.68       | 0.38 | 1.23            |
| Pinsornsak 2017  | 0                 | 45    | 0                  | 45    | 1.00       | 0.02 | 49.3            |
| Ha 2015          | 3                 | 31    | 5                  | 31    | 0.60       | 0.16 | 2.30            |
| Shin 2015        | 0                 | 39    | 0                  | 78    | 1.98       | 0.04 | 97.7            |
| Ryu 2014         | 0                 | 42    | 9                  | 85    | 0.11       | 0.01 | 1.78            |
| Park 2013        | 9                 | 109   | 3                  | 109   | 3.00       | 0.83 | 10.78           |
| Choi 2012        | 1                 | 60    | 2                  | 60    | 0.50       | 0.05 | 5.37            |
| Lee 2011         | 0                 | 60    | 0                  | 60    | 1.00       | 0.02 | 49.6            |
| Ansari 2010      | 5                 | 65    | 23                 | 65    | 0.22       | 0.09 | 0.54            |
| Choi 2010        | 2                 | 68    | 2                  | 71    | 1.04       | 0.15 | 7.20            |
| Hahm 2010        | 5                 | 42    | 11                 | 42    | 0.45       | 0.17 | 1.20            |
| Ryu 2010         | 0                 | 40    | 0                  | 80    | 1.98       | 0.04 | 97.8            |
| Yoon 2009        | 0                 | 35    | 0                  | 35    | 1.00       | 0.02 | 49.6            |
| Choi 2008        | 1                 | 47    | 1                  | 47    | 1.00       | 0.06 | 15.52           |
| Lee 2008         | 1                 | 50    | 0                  | 50    | 3.00       | 0.13 | 71.91           |
| Suh 2007         | 3                 | 29    | 6                  | 29    | 0.50       | 0.14 | 1.81            |
| Huh 2006         | 0                 | 25    | 0                  | 20    | 0.81       | 0.02 | 39.0            |

Random effects model
Heterogeneity: I-squared = 0%

Risk Ratio = 0.61 [0.43; 0.86]

B

Fig 7. Forrest plot and trial sequential analysis of postoperative vomiting (POV) in the next-day period. (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the next-day period POV was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g007
Fig 8. Forrest plot and trial sequential analysis for headache. (A) Forrest plot. RR, risk ratio, CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the early-period postoperative nausea was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g008
Fig 9. Forrest plot and trial sequential analysis for dizziness. (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the early-period postoperative nausea was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g009
results showed that the incidence of drowsiness did not differ significantly between ramose-
tron and ondansetron treatment groups (RR [95% CI] = 0.99 [0.82–1.19], I² = 0%) (Fig 10A). The subgroup analysis revealed that the differences according to bias risk and ondansetron
dose (4 mg vs. 8 mg) were not statistically significant (p = 0.93 and 0.68, respectively). The Z-
curve did not cross the TSA monitoring boundary or the futility boundary (TSA-adjusted CI = 0.72–1.35, Fig 10B). The GRADE was determined to be “low” because the TSA indicated that the result was imprecise.

Small-study effects
The funnel plots of the primary outcomes are shown in Fig 11. The asymmetry tests for these funnel plots were significant for early PON (p = 0.014) and late PON (p = 0.012), but not sig-
nificant for next-day PON (p = 0.19), early POV (p = 0.17), late POV (p = 0.35), and next-day
POV (p = 0.34). The asymmetry tests for headache (p = 0.71), dizziness (p = 0.81) and drowsi-
ness (p = 0.18) were also non-significant.

Risk of bias
The assessments of the bias risk in individual RCTs are shown in Table 3. There were six RCTs [6,23,25,31,33,40] with low bias risks in all domains. While 17 double-blinded RCTs should have given a low bias risk, the allocation concealment was unclear in 10 of them (Table 3).

Discussion
The findings of this updated meta-analysis were as follows: 1) Ramosetron was more effective in preventing late-period PON, late-period POV, and next-day PON than ondansetron; 2) the effect of ramosetron in preventing early-period PON may be greater than that of 4-mg ondan-
setron, but not of 8-mg ondansetron; 3) the incidence of dizziness may be significantly lower in patients receiving ramosetron than in patients receiving ondansetron, but the incidences of headache and drowsiness were similar in patients in both drug groups.

Our results indicate that ramosetron is more effective in preventing PON and POV in late (6–24 h) and next-day (24–48 h) periods than ondansetron. The GRADE was “moderate” for late PON and “high” for late POV and next-day PON. These findings could be explained by the longer duration of action of ramosetron. The elimination half-life of ramosetron is 9 h [2] whereas that of ondansetron is 3.5 h [44]. Therefore, ramosetron offered prolonged benefits in late or next-day periods. A previous observational study [45] reported that the incidence of POV or moderate-severe nausea was high 0–6 h and 6–24 h after surgery in high-risk patients (Apfel risk factors ≥ 3). Therefore, preventive strategies for PON and POV should aim to pre-
vent symptoms in the late period (6–24 hours) as well as in the early period (0–6 hours). The difference in the effects of ramosetron and ondansetron in the early period was statistically sig-
nificant, but we could not reach a firm conclusion because of the low quality of evidence (GRADE: low). Interpreting the results conservatively, we conclude that ramosetron had at least an equal effect to that of ondansetron in preventing early-period PON and POV. Thus, ramosetron could be recommended as a prophylactic drug for high-risk patients, since it was more effective in preventing PON and POV in the late period and was at least equally effective as ondansetron in the early period. However, cost-effectiveness studies comparing ramosetron and ondansetron should be conducted to support this strategy.

The GRADE score for the meta-analysis was “low” for early-period PON, early-period
POV, and next-day POV. The main reason for the low GRADE score was imprecisions revealed by TSA. The TSA results for these outcomes showed that the cumulative Z-curve did not cross either the TSA monitoring boundary or the futility boundary, which means that the
### A

| Study   | Ramosetron Events | Total | Ondanstron Events | Total | Risk Ratio | RR   | 95%-CI       |
|---------|-------------------|-------|-------------------|-------|------------|------|-------------|
| Joo 2016| 2                 | 32    | 4                 | 26    |            | 0.41 | [0.08; 2.05]|
| Jamwal 2016 | 3           | 50    | 5                 | 50    |            | 0.60 | [0.15; 2.38]|
| Suman 2017| 0               | 50    | 0                 | 50    |            | 1.00 | [0.02; 49.45]|
| Lee 2016 | 11               | 554   | 8                 | 548   |            | 1.36 | [0.55; 3.36]|
| Ha 2015  | 2                 | 31    | 5                 | 31    |            | 0.40 | [0.08; 1.91]|
| Shetty 2015 | 1          | 75    | 1                 | 75    |            | 1.00 | [0.06; 15.69]|
| Kaja 2014| 0                 | 30    | 1                 | 30    |            | 0.33 | [0.01; 7.86]|
| Ryu 2014 | 2                 | 42    | 9                 | 85    |            | 0.45 | [0.10; 1.99]|
| Park 2013| 11               | 109   | 7                 | 109   |            | 1.57 | [0.63; 3.90]|
| Choi 2012| 4                 | 60    | 2                 | 60    |            | 2.00 | [0.38; 10.51]|
| Ryu 2010 | 23               | 40    | 42                | 80    |            | 1.10 | [0.78; 1.54]|
| Yoon 2009| 1                 | 35    | 2                 | 35    |            | 0.50 | [0.05; 5.27]|
| Choi 2008| 0                 | 47    | 4                 | 47    |            | 0.11 | [0.01; 2.01]|
| Suh 2007 | 22               | 29    | 23                | 29    |            | 0.96 | [0.73; 1.26]|
| Huh 2006 | 8                 | 25    | 6                 | 20    |            | 1.07 | [0.44; 2.57]|

**Random effects model**

|    |    |
|----|----|
| 1209 | 1275 |

**Heterogeneity:** 1-squared = 0%

### B

**Fig 10. Forrest plot and trial sequential analysis for drowsiness.** (A) Forrest plot. RR, risk ratio; CI, confidence interval. (B) Trial sequential analysis. Risk of type I error was maintained at 5% with 90% power. The variance was calculated from data obtained from the trials included in this meta-analysis. A clinically meaningful anticipated RR of the early-period postoperative nausea was set at 0.75.

https://doi.org/10.1371/journal.pone.0186006.g010
results could not lead to firm conclusions. The TSA also revealed that the acquired sample size reached only 30% in the next-day POV analysis, possibly due to a low incidence of next-day POV. A previous observational study [45] revealed that the incidence of next-day POV was low even in high-risk patients. Thus, next-day POV prevention may not be important when determining a prophylactic strategy for PON and POV.

The test for subgroup differences indicated that the dose of ondansetron influenced its efficacy on early-period PON. The effect of ramosetron in preventing early PON was greater than that of 4-mg ondansetron, but not of 8-mg ondansetron. When prescribing 8-mg ondansetron in routine clinical practice, some physicians may be concerned about the US Food and Drug Administration (FDA) alert regarding QT interval prolongation with high-dose ondansetron [46]. The FDA states that "the 32 mg, single IV dose should be avoided due to the risk of a specific type of irregular heart rhythm called QT interval prolongation, which can lead to Tor-sades de Pointes, an abnormal, potentially fatal heart rhythm" [46] and "no single intravenous dose should exceed 16 mg" [46]. Therefore, 8 mg of ondansetron could be considered for prophylaxis when the main target is to prevent PON in the early period (0–6 h after surgery).

We analyzed the side effects of 5-HT$_3$ antagonists, including headache, dizziness, and drowsiness. The incidence of dizziness was significantly lower in patients receiving ramosetron.
than in patients receiving ondansetron (GRADE: low), but the incidences of headache and drowsiness did not differ for the two drugs (GRADE: low). We graded the quality of evidence of these outcomes as “low” because TSA revealed that the cumulative Z-curve did not cross the boundaries. More RCTs would be required to reach a firm conclusion regarding the comparative incidence of side effects of ramosetron and ondansetron.

There were limitations in our meta-analysis. First, the results of TSAs revealed that the acquired sample size did not reach the RIS (i.e., target sample size) in any primary outcome except for late PON. Although the results of late-period POV and next-day PON assessments showed that the cumulative Z-curve crossed the TSA monitoring boundary before reaching the RIS, the GRADE score was low for all other outcomes. To reach a firm conclusion, further RCTs are required to study the effects of the two drugs on early PON, early POV, and next-day POV. Second, we included only one RCT of pediatric patients in the meta-analysis. The overall risk of bias of the pediatric RCT was unclear, and thus, the RCT was excluded from our sensitivity analysis, restricting the analysis to high-quality RCTs. Therefore, our results cannot be extrapolated to pediatric patients.

In conclusion, the current meta-analysis shows that ramosetron is more effective at preventing late PON, late POV, and next-day PON than ondansetron, and may be associated with a lower incidence of dizziness.

Table 3. Risk of bias in individual trials.

| Sequence generation | Allocation concealment | Patients blinded | Health care providers blinded | Data collectors blinded | Outcome assessors blinded | Incomplete outcome data | Selective reporting | Other bias | summary   |
|---------------------|------------------------|-----------------|-------------------------------|-------------------------|---------------------------|------------------------|-------------------|-----------|-----------|
| Mujoo et al., 2017 [38] | Low                    | Unclear         | Low                           | Low                     | Low                       | Low                    | Unclear          | Low       | Unclear   |
| Pinsornsak et al., 2017 [40] | Low                  | Low             | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Low       |
| Suman et al., 2017 [39] | Low                    | Unclear         | Unclear                       | Unclear                 | Unclear                   | Unclear                | Low               | Unclear   | Unclear   |
| Joo et al., 2016 [41] | Low                    | Low             | Low                           | Low                     | Low                       | Low                    | Unclear          | Low       | Unclear   |
| Jamwal et al., 2016 [42] | Unclear               | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Unclear   |
| Lee et al., 2016 [18] | Low                    | Unclear         | Low                           | Low                     | Low                       | Low                    | Unclear          | Low       | Unclear   |
| Ha et al., 2015 [19] | Low                    | Low             | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Unclear   |
| Shetty et al., 2015 [21] | Low                   | Low             | Low                           | Unclear                 | Unclear                   | Unclear                | Low               | High      | High      |
| Agarkar and Chatterjee, 2015 [22] | Low               | Unclear         | Low                           | Unclear                 | Unclear                   | Unclear                | Low               | Low       | Unclear   |
| Shin et al., 2015 [20] | Low                    | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Unclear   |
| Gupta et al., 2014 [43] | Unclear               | Unclear         | Low                           | Low                     | Low                       | Low                    | Unclear          | Low       | Unclear   |
| Kaja et al., 2014 [24] | Low                    | Unclear         | Unclear                       | Unclear                 | Unclear                   | Unclear                | Low               | Low       | Unclear   |
| Ryu et al., 2014 [23] | Low                    | Low             | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Low       |
| Kim et al., 2013 [25] | Low                    | Low             | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Low       |
| Park et al., 2013 [26] | Low                    | Unclear         | Low                           | Unclear                 | Unclear                   | Unclear                | Low               | Low       | Unclear   |
| Choi et al., 2012 [27] | Low                    | Unclear         | Low                           | Unclear                 | Unclear                   | Unclear                | Low               | Low       | Unclear   |
| Lee et al., 2011 [28] | Low                    | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Unclear   |
| Ansari et al., 2010 [30] | Low                   | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Unclear   |
| Choi et al., 2010 [29] | Low                    | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Unclear   | Unclear   |
| Hahm et al., 2010 [31] | Low                    | Low             | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Low       |
| Ryu et al., 2010 [6]  | Low                    | Low             | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Low       |
| Kim et al., 2009 [33] | Low                    | Low             | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Low       |
| Yoon et al., 2009 [32] | Unclear               | Unclear         | Low                           | Unclear                 | Low                       | Low                    | Low               | Low       | Low       |
| Choi et al., 2008 [35] | Low                    | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Unclear   |
| Lee et al., 2008 [34] | Unclear               | Unclear         | High                          | Unclear                 | Unclear                   | Low                    | Low               | Low       | High      |
| Suh et al., 2007 [36] | Unclear               | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Low       |
| Huh et al., 2006 [37] | Unclear               | Unclear         | Low                           | Low                     | Low                       | Low                    | Low               | Low       | Unclear   |

https://doi.org/10.1371/journal.pone.0186006.t003
Supporting information

S1 Table. The PRISMA checklist.

(DOC)

Acknowledgments

We would like to thank Editage (www.editage.jp) for English language editing.

Author Contributions

Conceptualization: Takahiro Mihara, Takahisa Goto.
Data curation: Ayako Yokoi, Takahiro Mihara.
Formal analysis: Takahiro Mihara.
Investigation: Ayako Yokoi, Takahiro Mihara.
Methodology: Takahiro Mihara.
Resources: Takahisa Goto.
Software: Takahiro Mihara.
Supervision: Koui Ka, Takahisa Goto.
Writing – original draft: Ayako Yokoi, Takahiro Mihara.
Writing – review & editing: Takahiro Mihara, Koui Ka, Takahisa Goto.

References

1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014; 118: 85–113. https://doi.org/10.1213/ANE.0000000000000002 PMID: 24356162
2. Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc). 2002; 38: 75–89.
3. Mihara T, Tojo K, Uchimoto K, Morita S, Goto T. Reevaluation of the effectiveness of ramosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Anesth Analg. 2013; 117: 329–339. https://doi.org/10.1213/ANE.0b013e31829847a1 PMID: 23757469
4. Gao C, Li B, Xu L, Lv F, Cao G, Wang H, et al. Efficacy and safety of ramosetron versus ondansetron for postoperative nausea and vomiting after general anesthesia: a meta-analysis of randomized clinical trials. Drug Des Devel Ther. 2015; 9: 2343–2350. https://doi.org/10.2147/DDDT.S80407 PMID: 25960637
5. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. www.cochrane.org/training/cochrane-handbook (accessed 03/04/2017).
6. Ryu J, So Y-M, Hwang J, Do S-H. Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Surg Endosc. 2010; 24: 812–7. https://doi.org/10.1007/s00464-009-0670-5 PMID: 19707823
7. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JPA, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009; 38: 276–286. https://doi.org/10.1093/ije/dyn179 PMID: 18824467
8. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008; 61: 763–769. https://doi.org/10.1016/j.jclinepi.2007.10.007 PMID: 18411040
9. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive —Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009; 38: 287–298. https://doi.org/10.1093/ije/dyn188 PMID: 18824466
10. Wetterson J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008; 61: 64–75. https://doi.org/10.1016/j.jclinepi.2007.03.013 PMID: 1803463

11. Nüesch E, Jüni P. Commentary: Which meta-analyses are conclusive? Int J Epidemiol. 2009; 38: 298–303. https://doi.org/10.1093/ije/dyn265 PMID: 19074491

12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gatchis PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6: e1000100. https://doi.org/10.1371/journal.pmed.1000100 PMID: 19621070

13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072

14. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Allocco P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924–6. https://doi.org/10.1136/bmj.39489.470347.AD PMID: 18436948

15. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328: 1490. https://doi.org/10.1136/bmj.328.7454.1490 PMID: 15205295

16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–188. PMID: 3802833

17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629–34. PMID: 9310563

18. Lee Y-H, Seo J-H, Min K-T, Lim Y-J, Jeong S-W, Lee E-K, et al. Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. Br J Clin Pharmacol. 2016; 82: 762–772. https://doi.org/10.1111/bcp.13010 PMID: 27195435

19. Ha SH, Kim H, Ju HM, Nam DJ, Min KT. Comparison of the antiemetic effect of ramosetron with ondansetron in patients undergoing microvascular decompression with retromastoid craniotomy: a preliminary report. Korean J Anesthesiol. 2015; 68: 386. https://doi.org/10.4097/kjae.2015.68.4.386 PMID: 26257852

20. Shin H-J, Choi E-S, Lee G-W, Do S-H. Effects of Preoperative Serotonin-Receptor-Antagonist Administration in Spinal Anesthesia–Induced Hypotension. Reg Anesth Pain Med. 2015; 40: 583–588.

21. Shetty A, Panaych KPS, Bangera A, Prasad KP, NM P. A study of analogy and collation of intravenous ondansetron and intravenous ramosetron for the prevention of post operative nausea and vomiting following middle ear surgeries in a south indian tertiary care hospital: A prospective, randomized, double blind study. Int Res J Pharm. 2015; 6: 435–437.

22. Agarkar S, Chatterjee AS. Comparison of ramosetron for ondansetron for the prevention of post-operative nausea and vomiting in high-risk patients. Indian J Anaesth. 2015; 59: 222–227. https://doi.org/10.4103/0019-5049.154999 PMID: 25937648

23. Ryu J-H, Lee J-E, Lim Y-J, Hong D-M, Park H-P, Han J-I, et al. A prospective, randomized, double-blind, and multicenter trial of prophylactic effects of ramosetron postoperative nausea and vomiting (PONV) after craniotomy: comparison with ondansetron. BMC Anesthesiol. 2014; 14: 63. https://doi.org/10.1186/1471-2253-14-63 PMID: 25104916

24. Kaja S, Giri RS, Tugave D V, Iqbal M. A randomized clinical trial comparing the efficacy and safety of ramosetron versus ondansetron in patients undergoing abdominal surgery under general anesthesia. Saudi J Anaesth. 2014; 8: 59–63. https://doi.org/10.4103/1658-354X.125938 PMID: 24665241

25. Kim S-H, Hong J-Y, Kim WO, KI HK, Karm M-H, Hwang J-H. Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: A prospective, randomized, double-blinded study. Korean J Anesthesiol. 2013; 64: 517–523. https://doi.org/10.4097/kjae.2013.64.6.517 PMID: 23814652

26. Park Y-H, Jang Y-E, Byon H-J, Kim J-T, Kim H-S. Comparison of the efficacy of ramosetron and ondansetron in the prophylaxis of postoperative vomiting in children receiving fentanyl by patient-controlled analgesia after orthopedic surgery: a randomized controlled trial. J Pain Palliat Care Pharmacother. 2013; 23: 360–364.

27. Choi YS, Shim J, Ahn S, Kwak YL. Efficacy comparison of ramosetron with ondansetron on preventing nausea and vomiting in high-risk patients following spine surgery with a single bolus of dexamethasone as an adjunct. Korean J Anesthesiol. 2012; 62: 543–547. https://doi.org/10.4097/kjae.2012.62.6.543 PMID: 22778890

28. Park HJ, Choi J, Park SJ, Kang H, Kim E-G. Comparison of ramosetron's and ondansetron's preventive anti-emetic effects in highly susceptible patients undergoing abdominal hysterectomy. Korean J Anesthesiol. 2011; 61: 488–92. https://doi.org/10.4097/kjae.2011.61.6.488 PMID: 22220226
29. Choi DK, Chin JH, Lee EH, Lim OB, Chung CH, Ro YJ, et al. Prophylactic control of post-operative nausea and vomiting using ondansetron and ramosetron after cardiac surgery. Acta Anaesthesiol Scand. 2010; 54: 962–9. https://doi.org/10.1111/j.1399-6576.2010.02275.x PMID: 20626355

30. Ansari MM, Siddiqui OA, Haleem S, Varshney R, Akhtar S, Khan FA. Comparison of ramosetron and ondansetron for control of post-operative nausea and vomiting following laparoscopic cholecystectomy. Indian J Med Sci. 2010; 64: 272–280.

31. Hahm TS, Ko JS, Choi SJ, Gwak MS. Comparison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement. Anaesthesia. 2010; 65: 500–504. https://doi.org/10.1111/j.1365-2044.2010.06310.x PMID: 20337618

32. Yoon DG, Jung SH, Ha MH, Song NW. Comparison of ramosetron and ondansetron for preventing nausea and vomiting after middle ear surgery under general anesthesia with sevoflurane and remifentanil. Korean J Anesthesiol. 2009; 56: 408–412.

33. Kim SI, Kim SC, Baek YH, Ok SY, Kim SH. Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery. Br J Anaesth. 2009; 103: 549–53. https://doi.org/10.1093/bja/aep209 PMID: 19700442

34. Lee H-J, Shin C-S, Choi B-S, Yoon J-Y, Kwon J-Y, Kim H-K. Effect of oral ramosetron for postoperative nausea and vomiting in surgical patients using patient controlled analgesia. Korean J Anesthesiol. 2008; 54: 63–68.

35. Choi YS, Shim JK, Yoon DH. Effect of ramosetron on patient-controlled analgesia related nausea and vomiting after spine surgery in highly susceptible patients: comparison with ondansetron. Spine (Phila Pa 1976). 2008; 33: E602–6.

36. Suh J-H, Kang M-H, Ryu J-HH, Park K-SS, Do S-HH. Comparison of ramosetron and ondansetron for preventing nausea and vomiting after gynecologic surgery. Korean J Anesthesiol. 2007; 52: 561–565.

37. Huh IY, Cheon MY, Choi IC. Comparison of prophylactic antiemetic therapy with patient-controlled epidural analgesia after thoracotomy. Korean J Anesthesiol. 2006; 51: 70–75.

38. Mujoo S, Ali Z, Jehangir M, Iqbal A, Qayoom N, Lone AQ. A Comparative Evaluation of Ramosetron With Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Urological Procedures. Anesth essays Res. 2017; 11: 78–83. https://doi.org/10.4103/0259-1162.200244 PMID: 28298761

39. Suman BR, Umesh R, Rohan B. A Comparative Study of Intravenous Ondansetron, Granisetron and Ramosetron for Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Cesarean Section. J Evol Med Dent Sci. 2017; 6: 575–580.

40. Pinsornsak P, Teeyaphudit M, Ruetiwarangkoon C, Chaiwuttisak A. Comparison of Ramosetron With Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial. J Arthroplasty. 2017; 32: 1040–1043. https://doi.org/10.1016/j.arth.2016.09.013 PMID: 27816366

41. Joo J, Park S, Park HJ, Shin SY. Ramesetron versus ondansetron for postoperative nausea and vomiting in strabismus surgery patients. BMC Anesthesiol. 2016; 16: 41. https://doi.org/10.1186/s12871-016-0210-5 PMID: 27449404

42. Jamwal A, Jatindera M, Wakhloo R, Kour R. Safety profile of various 5HT3 receptor antagonists used for PONV prophylaxis. JK Sci. 2016; 18: 111–115.

43. Gupta K, Mehta N, Mahotra K, Matto J. Comparative study of ondansetron, granisetron and ramosetron for prevention of postoperative nausea and vomiting (PONV) in surgeries under general anaesthesia. Indian J Basic Appl Med Res. 2014; 3: 701–705.

44. Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005; 19: 225–238. PMID: 15740177

45. White PF, Sacan O, Nuangchamnong N, Sun T, Eng MR. The relationship between patient risk factors and early versus late postoperative emetic symptoms. Anesth Analg. 2008; 107: 459–463. https://doi.org/10.1213/ane.0b013e31817aae6e PMID: 18633024

46. FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products. http://www.fda.gov/Drugs/DrugSafety/ucm330049.htm (accessed 03/04/2017).